Drug Trial Radar · NCT05907057
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
245
Planned (sponsor's estimate)
Start
Jun 14, 2023
Primary completion
Oct 15, 2027
Study completion Oct 15, 2027
Sponsor
- Lead sponsor
- Servier Affaires MédicalesIndustry
- Sponsor type
- Industry
- First posted
- Jun 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn more about the safety and efficacy of ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who are presenting a gene mutation called IDH1 (isocitrate dehydrogenase1 mutation-positive \[IDH1m\]) and cannot receive treatment with intensive chemotherapy (IC).
Conditions
- Acute Myeloid Leukemia (AML)
Interventions
Ivosidenib 500mg Oral TabletDrug
Provided as tablets, taken orally as two 250mg tablets once daily.
AzacitidineDrug
Administered subcutaneously (SC) or intravenously (IV) at a dose of 75mg/m2/day for 7 days, either consecutively on Days 1-7 or discontinuously for Days 1-5 and 8-9 of each cycle. The 7 days of administration will occur at the beginning of every 4 week-long cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events (AEs)Time frame: up to week 116
- Number of Serious Adverse Events (SAEs)Time frame: up to week 116
- Differentiation Syndrome of Grade 2 or higherTime frame: up to week 116
- Number of Adverse Events (AEs) leading to ivosidenib + azacitidine discontinuationTime frame: up to week 112
- Number of Adverse Events (AEs) leading to ivosidenib + azacitidine interruptionTime frame: up to week 112
- Number of Adverse Events (AEs) leading to ivosidenib + azacitidine dose reductionTime frame: up to week 112
- Number of Adverse Events (AEs) leading to deathTime frame: up to week 116
- Number of clinical laboratory anomalies assessed as Adverse Events (AEs)Time frame: up to week 116
- Number of patients requiring transfusion (platelet and RBC) and the average number of units transfusedTime frame: up to week 116
- Rate of infectionsTime frame: up to week 116
- QT Prolongation event assessed as Grade 3 or higherTime frame: up to week 116
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
AKH - Medizinische Universität Wien
Vienna, Austria · Completed
Klinikum Wels-Grieskirchen GmbH
Wels, Austria · Completed
Institut Paoli Calmettes
Marseille, Bouches-du-Rhône, France · Recruiting
CHU CAEN - Hôpital de la Côte de Nacre
Caen, Calvados, France · Recruiting
CHU de Toulouse pt
Toulouse, Haute Garonne, France · Recruiting
CHU Rennes - Hopital Pontchaillou
Rennes, Ille Et Vilaine, France · Not yet recruiting
CHU Angers - Hôpital Hôtel Dieu
Angers, Liore, France · Not yet recruiting
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)
Brescia, Italy · Recruiting
IRCCS Ospedale Policlinico San Martino
Genova, Italy · Recruiting
Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
Perugia, Italy · Recruiting
IRCCS Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - IRST
Meldola, Forli-Cesena, Italy · Recruiting
Meander Medisch Centrum
Amersfoort, Netherlands · Recruiting
Amsterdam UMC
Amsterdam, Netherlands · Recruiting
Rijnstate
Arnhem, Netherlands · Not yet recruiting
Universitair Medisch Centrum Groningen
Groningen, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.